| Barkly Rare Earths Limited (BAK) ORDINARY FULLY PAID |
Materials |
$10 |
Barkly Rare Earths Completes Successful IPO
|
30 Jan 2026 10:50AM |
n/a |
$0.180 |
n/a
|
|
| Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID |
Health Care |
$677 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 10:50AM |
$3.160 |
$1.815 |
fallen by
42.56%
|
|
CU6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Net operating cash outflow of $25.1 million for December quarter.
- Advancement of clinical trials: AMPLIFY and CLARIFY.
- Building supply chain for copper isotopes.
- Supply agreement for copper-67 with Nusano.
- FDA Fast Track Designations for SAR-bisPSMA agent.
- Co-PSMA trial achieved primary endpoint.
- Estimated funding available for nine quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| I Synergy Group Limited (IS3) ORDINARY FULLY PAID |
Information Technology |
$18 |
December Quarterly Appendix 4C
|
30 Jan 2026 10:50AM |
$0.011 |
$0.260 |
risen by
2,263.64%
|
|
IS3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash used in operating activities: AUD 85,000.
- Cash equivalents decreased to AUD 546,000 by quarter-end.
- No financing facilities were drawn during the quarter.
- Estimated 6.42 quarters of funding available based on current cash burn rate.
- Prepared in compliance with ASX Listing Rule 4.7B.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Raptor Metals Ltd (RAP) ORDINARY FULLY PAID |
Materials |
$16 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:47AM |
$0.059 |
$0.040 |
fallen by
32.20%
|
|
RAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Raptor Metals Ltd reports net cash outflow from operating activities of $135,000.
- Net cash from investing activities was $20,000 for the quarter.
- Financing activities resulted in a net inflow of $4.884 million.
- Cash and cash equivalents at quarter's end totaled $5.057 million.
- The company focuses on Canadian copper exploration in Bathurst Mining Camp.
- Estimated 37.5 quarters of funding available based on current cash flow.
- Related party payments amounted to $91,000, covering director and consulting fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lord Resources Limited (LRD) ORDINARY FULLY PAID |
Materials |
$2 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:46AM |
$0.022 |
$0.013 |
fallen by
40.91%
|
|
LRD - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash from operating activities: -$757,000
- Exploration and evaluation expenditure: $855,000
- Ilgarari Copper Project drilling confirmed high-grade copper
- No activities for Horse Rocks and Jingjing Lithium Projects
- Cash and cash equivalents at the end of the quarter: $890,000
- Entitlement offer did not proceed
- Planned reduction in exploration expenditure next quarter
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Credit Clear Limited (CCR) ORDINARY FULLY PAID |
Information Technology |
$78 |
Becoming a substantial holder
|
30 Jan 2026 10:44AM |
$0.250 |
$0.150 |
fallen by
40%
|
|
| Larvotto Resources Limited (LRV) ORDINARY FULLY PAID |
Materials |
$623 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:43AM |
$1.485 |
$1.200 |
fallen by
19.19%
|
|
LRV - Price-sensitive ASX Announcement
Full Release
Key Points
- Larvotto Resources Limited recorded a net cash outflow from operating activities of AUD 2.785 million for the quarter.
- Significant expenditures were noted in exploration and evaluation, staff costs, and administration.
- Cash outflows from investing activities amounted to AUD 31.631 million.
- Financing activities generated AUD 86.087 million primarily from equity securities and borrowings.
- The company is advancing the Hillgrove Antimony-Gold Project with promising drilling results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Palladium Limited (SPD) ORDINARY FULLY PAID |
Materials |
$131 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:43AM |
$2.320 |
$0.990 |
fallen by
57.33%
|
|
SPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly activities and cash flow report for the period ending 31 December 2025.
- Advancement of Definitive Feasibility Study for the Bengwenyama PGM Project.
- Cash balance of A$22.58 million as of 31 December 2025.
- Successful A$20 million placement to support project development.
- Lodgement of the Environmental Guarantee as a key regulatory milestone.
- Payments to related parties amounting to A$674,000.
- No disposal of tenements during the quarter.
- Ongoing development of the Bengwenyama Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| C29 Metals Limited (C29) ORDINARY FULLY PAID |
Materials |
$5 |
Change of Director's Interest Notice
|
30 Jan 2026 10:42AM |
$0.030 |
$0.023 |
fallen by
23.33%
|
|
| C29 Metals Limited (C29) ORDINARY FULLY PAID |
Materials |
$5 |
Notification of cessation of securities - C29
|
30 Jan 2026 10:38AM |
$0.030 |
$0.023 |
fallen by
23.33%
|
|
| C29 Metals Limited (C29) ORDINARY FULLY PAID |
Materials |
$5 |
Proposed issue of securities - C29
|
30 Jan 2026 10:37AM |
$0.030 |
$0.023 |
fallen by
23.33%
|
|
| Perennial Income Generator Fund (Managed Fund) (EIGA) |
Financials |
$27 |
EIGA Monthly Portfolio Disclosure
|
30 Jan 2026 10:36AM |
$3.750 |
$3.710 |
fallen by
1.07%
|
|
| Legacy Minerals Holdings Limited (LGM) ORDINARY FULLY PAID |
Materials |
$21 |
Cleansing Notice - Options Exercised
|
30 Jan 2026 10:36AM |
$0.215 |
$0.105 |
fallen by
51.16%
|
|
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
2025 Q4 Quarterly Activities Report & Appendix 4C
|
30 Jan 2026 10:35AM |
$0.400 |
$0.305 |
fallen by
23.75%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $29.0m, up 10% on prior year.
- Underlying EBITDA of $1.6m, at the top end of guidance.
- Annual recurring revenue (ARR) of $34.8m, up 16% year-over-year.
- Q4 FY25 software revenue of $2.4m, representing 25% growth.
- Cash and cash equivalents of $3.3m at end of December 2025.
- Strong operational focus and execution improvement.
- Significant software and radiology service performance increase.
- Release of new software features, including AI agents.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| I Synergy Group Limited (IS3) ORDINARY FULLY PAID |
Information Technology |
$18 |
December Quarterly Activities Report
|
30 Jan 2026 10:35AM |
$0.011 |
$0.260 |
risen by
2,263.64%
|
|
IS3 - Price-sensitive ASX Announcement
Full Release
Key Points
- I Synergy Group Limited announced December Quarter Statement of Activity and Cash Flows.
- Operational update includes early-stage activities in AI infrastructure and digital technologies.
- Entered non-exclusive lease agreements for high-performance computing and AI software.
- Strategic lease agreements aim to establish recurring revenue streams.
- Notice of Extraordinary General Meeting scheduled for 2 February 2026.
- Payments to related parties totaled approximately $63,000.
- Transitioning from affiliate marketing to new growth avenues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| C29 Metals Limited (C29) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:34AM |
$0.030 |
$0.023 |
fallen by
23.33%
|
|
C29 - Price-sensitive ASX Announcement
Full Release
Key Points
- Focused on administrative tasks and planning for Sampsons Tank Copper project.
- Exploring new acquisition opportunities globally.
- Ended the quarter with $211,000 cash.
- Entered a $150,000 convertible loan agreement with a director.
- Plans to raise further capital based on past success.
- Payments to related parties totaled $136,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| eInvest Better Future (Managed Fund) (IMPQ) |
Financials |
$32 |
IMPQ Monthly Portfolio Disclosure
|
30 Jan 2026 10:34AM |
$4.860 |
$4.380 |
fallen by
9.88%
|
|
| AVA Risk Group Limited (AVA) ORDINARY FULLY PAID |
Information Technology |
$10 |
Cleansing Notice
|
30 Jan 2026 10:34AM |
$0.065 |
$0.035 |
fallen by
46.15%
|
|
AVA - Price-sensitive ASX Announcement
Full Release
Key Points
- AVA Risk Group Limited issued a Cleansing Notice under section 708A of the Corporations Act.
- The Cleansing Notice pertains to the issuance of Tranche 1 Notes and Tranche 1 Warrants.
- AVA entered into a Convertible Note Facility and Warrant Deed with Hale Capital Management.
- The initial drawdown of $2,979,184 was completed with Hale subscribing to 2,979,184 convertible notes.
- The conversion price for the notes is set at $0.1234 per share.
- AVA also issued 19,314,000 unlisted warrants exercisable at the same price for five years.
- A further potential funding of $4,020,816 through Tranche 2 Notes is subject to shareholder approval.
- The funding aims to support AVA’s working capital and growth initiatives in the US market.
- The conversion or exercise of these securities may significantly affect AVA’s capital structure.
- Conditions including shareholder approval are necessary for the Tranche 2 issuance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PEXA Group Limited (PXA) ORDINARY FULLY PAID |
Real Estate |
$1,796 |
Revised Timeline for IPART ELNO Fee review
|
30 Jan 2026 10:34AM |
$13.800 |
$10.210 |
fallen by
26.01%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$21 |
OncoSil delivers strong early clinical results in Turkiye
|
30 Jan 2026 10:32AM |
$0.800 |
$0.675 |
fallen by
15.63%
|
|
| Cobalt Blue Holdings Limited (COB) ORDINARY FULLY PAID |
Materials |
$38 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:32AM |
$0.083 |
$0.065 |
fallen by
21.69%
|
|
COB - Price-sensitive ASX Announcement
Full Release
Key Points
- COB received a $1.2 million ATO Research and Development rebate.
- The company raised $5.3 million through an oversubscribed placement.
- Cobalt Blue is progressing towards a final investment decision for the Kwinana Cobalt Refinery.
- The Broken Hill Technology Centre is focusing on evaluating battery black mass as a potential feedstock.
- COB's cash position increased to $6.72 million by the end of the quarter.
- The company reduced staff salaries by 25% to 30% temporarily to preserve cash.
- Cobalt Blue aims to integrate recycled battery material into its business plan.
- COB confirmed no significant changes in its tenement holdings during the quarter.
- The company is engaging with potential offtake partners and exploring further financing options.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Legacy Minerals Holdings Limited (LGM) ORDINARY FULLY PAID |
Materials |
$21 |
Application for quotation of securities - LGM
|
30 Jan 2026 10:32AM |
$0.215 |
$0.105 |
fallen by
51.16%
|
|
| Omnia Metals Group Limited (OM1) ORDINARY FULLY PAID |
Materials |
$7 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 10:31AM |
$0.025 |
$0.018 |
fallen by
28%
|
|
OM1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed first-pass SLRC drilling at Salt Creek Project.
- Drilling provided key geological and geochemical data.
- Successfully completed $1.58 million placement.
- Company focuses on securing antimony, silver, and REE projects.
- Net cash increase to $1.708 million.
- No significant mineralization found at Salt Creek.
- Estimated funding available for over five quarters.
- Exploration in Western Australia and potential U.S. acquisitions.
- Continued strategic positioning through partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aguia Resources Limited (AGR) ORDINARY FULLY PAID |
Materials |
$47 |
Trading Halt
|
30 Jan 2026 10:31AM |
$0.024 |
$0.021 |
fallen by
12.50%
|
|
AGR - Price-sensitive ASX Announcement
Full Release
Key Points
- Aguia Resources Limited requests a trading halt on its securities.
- The halt is pending a fund raising announcement.
- The trading halt will last until the announcement is released or by 3 February 2026.
- ASX Listing Rule 17.1 has been referenced for the trading halt.
- Company Secretary Ross Pearson signed the request.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
Q2 FY26 Activities Report and Appendix 4C
|
30 Jan 2026 10:27AM |
$0.100 |
$0.076 |
fallen by
24%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly sales increased by 80% compared to the corresponding quarter in FY25.
- ReNerve Limited completed a capital raise, securing $2.6 million in financing.
- The company achieved hospital approvals for the NervAlign® Nerve Cuff in the US Department of Defence and Veterans Affairs hospital network.
- ReNerve launched its Empliq product ranges, including human tissue products.
- The company continues to focus on product development, aiming for NervAlign® Nerve Conduit market entry in 1H CY2026.
- The quarterly cash flow report showed closing cash of $4.18 million.
- ReNerve is advancing a complete suite of nerve repair solutions, including the NervAlign® Nerve Cuff and Nerve Conduit Range.
- The company anticipates strong growth and is focused on securing approval for products in additional markets, including India and Europe.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
